XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B | 8-K: FY2025 Q2 Revenue: USD 13.13 M

LB filings
2025.08.13 11:47
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 13.13 M.

EPS: As of FY2025 Q2, the actual value is USD 0.44.

Segment Revenue

  • XOMA Royalty received $29.6 million in royalties and milestones from its partners in the first half of 2025, including $11.7 million during the second quarter.

Operational Metrics

  • Net income for the three and six months ended June 30, 2025, was $9.2 million and $11.6 million, respectively, compared to $16.0 million and $7.4 million for the corresponding periods of 2024.
  • General and Administrative (G&A) expenses for the three and six months ended June 30, 2025, were $7.8 million and $15.9 million, respectively, compared to $11.0 million and $19.5 million for the corresponding periods of 2024.
  • Research and Development (R&D) expenses for the three and six months ended June 30, 2025, were $0.1 million and $1.4 million, respectively, compared to $1.2 million for each of the corresponding periods of 2024.

Cash Flow

  • Net cash provided by operating activities was $8.7 million for the six months ended June 30, 2025, compared to - $2.2 million for the corresponding period in 2024.
  • Net cash used in investing activities was - $26.7 million for the six months ended June 30, 2025, compared to - $1.4 million for the corresponding period in 2024.
  • Net cash used in financing activities was - $9.9 million for the six months ended June 30, 2025, compared to - $6.1 million for the corresponding period in 2024.

Unique Metrics

  • XOMA Royalty deployed $20 million to purchase future mezagitamab royalty and milestone interests held by BioInvent, with additional payments contingent on regulatory milestones.

Outlook / Guidance

  • XOMA Royalty anticipates becoming cash flow positive on a consistent basis exclusively from cash payments received from royalties as new commercial opportunities emerge.
  • The company expects to complete the acquisition of HilleVax in September and LAVA Therapeutics in the fourth quarter of 2025.
  • Topline data from several key Phase 3 assets are anticipated over the coming quarters, which may drive increased royalty receipts.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.